The Alcadeins (Alcs)/calsyntenins and the amyloid ␤-protein precursor (APP) associate with each other in the brain by binding via their cytoplasmic domains to X11L (the X11-like protein). We previously reported that the formation of this APP-X11L-Alc tripartite complex suppresses the metabolic cleavages of APP. We show here that the metabolism of the Alcs markedly resembles that of APP. The Alcs are subjected to a primary cleavage event that releases their extracellular domain. Alcs then undergo a secondary presenilin-dependent ␥-cleavage that leads to the secretion of the amyloid ␤-protein-like peptide and the liberation of an intracellular domain fragment (AlcICD). However, when Alc is in the tripartite complex, it escapes from these cleavages, as does APP. We also found that AlcICD suppressed the FE65-dependent gene transactivation activity of the APP intracellular domain fragment, probably because AlcICD competes with the APP intracellular domain fragment for binding to FE65. We propose that the Alcs and APP are coordinately metabolized in neurons and that their cleaved cytoplasmic fragments are reciprocally involved in the regulation of FE65-dependent gene transactivation. Any imbalance in the metabolism of Alcs and APP may influence the FE65-dependent gene transactivation, which together with increased secretion of amyloid ␤-protein may contribute to neural disorders.
The deposition and accumulation of amyloid ␤-protein (A␤) 1 in the human brain are hallmarks of Alzheimer's disease (AD) (1) . Amyloid ␤-protein precursor (APP) is the precursor of A␤. It has a receptor-like transmembrane protein structure that consists of an extracellular domain, a transmembrane domain, and a short carboxyl-terminal cytoplasmic domain (2) . The cytoplasmic domain of APP controls its metabolism and various physiological functions by interacting with cytoplasmic adaptor proteins (3) (4) (5) (6) (7) (8) . One of these adaptor proteins is X11L (the X11-like protein), which associates with the cytoplasmic domain of APP and stabilizes APP metabolism (5, 9) . During our previous research that aimed to reveal the molecular mechanism by which X11L regulates APP metabolism, we found that the Alcadeins, which form cadherin-related membrane protein family, are X11-and X11L-binding proteins (9) . These proteins are also known as calsyntenins, which were originally isolated as postsynaptic Ca 2ϩ -binding membrane proteins, but whose functions were not identified (10, 11) . The Alcadeins (Alcs) consist of two Alc␣ isoforms (Alc␣1 and Alc␣2) and Alc␤ and Alc␥, all of which are type I transmembrane proteins and contain a conserved X11L-binding motif in their single cytoplasmic domains, similar to APP (9) .
Alc does not directly interact with the cytoplasmic domain of APP. Rather, the association between the two molecules is bridged by the phosphotyrosine interaction domain of X11L. This results in the formation of a tripartite complex in the brain (9) . The formation of this complex enhances the X11L-mediated stabilization of APP metabolism and suppresses the generation of A␤. Through its interaction with X11L, Alc also forms another tripartite complex with a carboxyl-terminal fragment of APP (CTF) that resulted from its cleavage at the ␣-and/or ␤-sites. The Alc-X11L-CTF␤ complex promotes the X11L-dependent inhibition of the ␥-secretase cleavage of the CTF␤ because the complexing of CTF␤ interferes with its interaction with presenilin (PS) (9) . Moreover, it has been shown that APP and Alc co-localize in neurons (9) and that calsyntenin-1 is extracellularly cleaved (10) . This suggests that APP and Alc may be metabolized in a coordinated fashion by a secretase(s).
In the present study, we found that, like APP, the Alcs are cleaved by the PS-dependent ␥-secretase after a primary cleavage in their extracellular juxtamembrane region. These cleavages lead to the secretion of an A␤-like short peptide (␤-Alc) and liberate the intracellular domain of Alc (AlcICD). AlcICD down-regulates the gene transactivation ability of the APP intracellular domain (AICD). These observations suggest that APP and Alc are coordinately metabolized to regulate the gene transactivation ability of APP. This indicates that these two proteins play an important role in neural functions. Impairment of the coordinated metabolic regulation of APP and Alc and the consequent loss of the reciprocal regulation by APP and Alc in the gene transactivation may lead to neural disorders and disease progression in AD.
MATERIALS AND METHODS
Plasmid Construction-Human Alcadein cDNAs were inserted into pcDNA3 vector to construct pcDNA3-hAlc␣1, pcDNA3-hAlc␤, and pcDNA3-hAlc␥ as previously described (9) . The FLAG sequence was inserted between Leu 38 and Glu 39 of hAlc␣1cDNA (pcDNA3-FLAGhAlc␣1) and between Ile 41 and Glu 42 of hAlc␤cDNA (pcDNA3-FLAGhAlc␤), whereas the HA sequence was inserted between Ile 44 and Glu
45
of hAlc␥cDNA (pcDNA3-HA-hAlc␥). The amino acids between Glu 39 and Ala 815 of pcDNA3-FLAG-hAlc␣1 was deleted to produce pcDNA3-Alc␣⌬E. The pcDNA3-PS1 and pcDNA3-PS1D385A (12), pcDNA3APP695 (13) , and pcDNA3-hX11L (5) plasmids have been described previously. cDNAs encoding human AICD (residues 652-695 of human APP695) and human Alc␣ICD (residues 871-971 of human Alc␣1) were produced by PCR, and the products bearing the linker sequence encoding EFPGIPPG at their 5Ј-end were cloned into the pBIND vector (Promega) at the KpnI/BamHI sites. This generated pBIND-Gal4BD-AICD and pBIND-Gal4BD-Alc␣ICD, which encode fusion protein composed of Gal4BD linked to AICD or Alc␣ICD. The same procedure was used to generate the pBIND-Gal4BD-Alc␣ICD/NPAA plasmid, which expresses a mutant hAlc␣ICD molecule in which Asn 903 and Pro 904 were substituted by Ala. The Alc␣ICD and Alc␣ICD/NPAA cDNAs followed by the signal peptide sequence composed of 28 amino acid residues were also inserted into pcDNA3 to produce pcDNA3-hAlc␣ICD and pcDNA3-hAlc␣ICD/NPAA. FE65 cDNA (8) was inserted into pcDNA3.1 at the NheI/NotI sites to generate pcDNA3.1NFLAG-FE65. This construct produces FE65 bearing a FLAG tag at its amino terminus.
Antibodies-The anti-Alc␣ polyclonal rabbit antibody UT83 has been described (9) . The anti-Alc␤ polyclonal rabbit antibody UT99 was raised against a peptide composed of Cys plus the sequence between positions 951 and 968 of human Alc␤ (CϩDSPSSDERRIIETPPHRY). The antiAlc␥ polyclonal rabbit antibody UT105 was raised against a peptide composed of Cys plus the sequence between positions 938 and 955 of human Alc␥ (CϩQNGARQAQLEWDDSTLPY). These Alc-specific antibodies all recognize the cytoplasmic domain of the Alc proteins to which they had been raised. As a result, they recognized the full-length Alc protein, the CTF1 derived from Alc, and AlcICD. These antibodies did not react with other Alc proteins apart from the one to which they had been raised. The anti-APP cytoplasmic G369 antibody has been described (14) , and another anti-APP antibody was purchased from Sigma (catalog number A8717). The anti-X11L (mint2; BD Biosciences), anti-FLAG (M2; Sigma), anti-HA (12CA5; Roche Applied Science), anti-PS1 amino-terminal fragment (PS-NTF; Chemicon International), and anti-PS1 carboxyl-terminal fragment (PS-CTF; Chemicon International) antibodies were purchased.
In Vitro Generation of AlcICD-The cells were homogenized in 8 volumes of buffer A (10 mM triethanolamine-acetic acid buffer, pH 7.8, 0.25 M sucrose) containing 5 g/ml chymostatin, 5 g/ml leupeptin, and 5 g/ml pepstatin and centrifuged at 1,000 ϫ g for 10 min at 4°C. The supernatant was then centrifuged at 100,000 ϫ g for 15 min at 4°C to obtain the membrane fraction (15) . The membrane fraction was resuspended in buffer A containing 5 g/ml chymostatin and 5 g/ml leupeptin and incubated at 37°C for the indicated periods in the presence or absence of 1 M L-685,458, an aspartic protease inhibitor (Calbiochem). These samples were separated by electrophoresis through a Tris-Tricine gel (15% (w/v) polyacrylamide) and subjected to Western blotting.
Western Blot Assays-Human embryonic kidney (HEK) 293 cells (ϳ1 ϫ 10 7 cells) were transfected as described previously (9) with the indicated amounts of various combination of plasmids. The cells were harvested and lysed in Hepes-buffered saline with Triton X-100 (HBST; 10 mM Hepes, pH 7.4, 0.5% (v/v) Triton X-100, 150 mM NaCl, 5 g/ml chymostatin, 5 g/ml leupeptin, and 5 g/ml pepstatin). The cell lysate or immunoprecipitates were separated on Tris-glycine or Tris-Tricine gels, transferred to nitrocellulose membrane, and probed with specific antibodies. PS1-deficient, PS1-and PS2-deficient, and wild type fibroblast cells (16) were also transfected by the same procedure.
Protein Sequence Analysis-Alc␣1 and its CTF1 fragment were separated on SDS-PAGE and blotted on polyvinylidene difluoride membrane. The proteins corresponding Alc␣1 and CTF1 on the membrane were cut off and then subjected to the gas phase protein sequencer Procise 492HT (Applied Biosystems).
Immunostaining of Cells-HEK293 cells expressing FLAG-FE65 and Alc␣ICD were fixed in phosphate-buffered saline containing 4% (w/v) paraformaldehyde and 4% (w/v) sucrose, permeabilized in phosphatebuffered saline containing 0.2% (v/v) Triton X-100, blocked in phosphate-buffered saline containing 3% (w/v) bovine serum albumin, and incubated with the anti-FLAG monoclonal M2 antibody (1:500 dilution) and the anti-Alc␣ polyclonal antibody UT83 (0.8 g/ml IgG). After washing, the cells were further incubated with goat anti-rabbit IgG coupled with Alexa Fluor 488 or goat anti-mouse IgG coupled with Alexa Fluor 546 antibody. The cells were viewed using the confocal laser scanning microscope LSM510 (Carl Zeiss).
Gene Transactivation Assay-The indicated cells (ϳ3 ϫ 10 4 cells) plated in 96-multiwell plate were transiently transfected with various combinations of the following plasmids in LipofectAMINE 2000 (Invitrogen): pBIND-Gal4BD-AICD or pBIND-Gal4BD-Alc␣ICD (20 ng), pG5luc (600 ng) (Promega), and pcDNA3.1NFLAG-FE65 or pcDNA3.1NFLAG vector (40 ng) in the presence or absence of pcDNA3-hAlc␣ICD or pcDNA3-hAlc␣ICD/NPAA. To standardize the plasmid amount, pcDNA3 or pBIND-Gal4 vector (Ϫ) was added (to yield 0.7 g of plasmid in total). In a separate study, pBIND-APP695-Gal4BD was used instead of pBIND-Gal4BD-AICD. The cells were harvested 36 h after transfection, and the transcriptional activity of the reporter gene was analyzed by using the dual luciferase assay system (Promega). All of the combinations were tested in triplicate, and the luciferase activity was normalized according to the manufacturer's protocol to eliminate the effect of transfection efficiency differences.
RESULTS

Alcs Are Metabolized in a Similar Manner to APP and Are
Novel Substrates for PS-dependent ␥-Secretase-We previously reported that Alc and APP form a tripartite complex by cytoplasmic interactions with X11L, that the three proteins colocalize in neurons, and that tripartite complex formation stabilizes APP metabolism (9) . Alcs are type I membrane proteins, as is APP, and a previous report has suggested that the Alc/ calsyntenin proteins are cleaved extracellularly (10) . These observations led us to speculate that the Alcs are metabolized in a similar manner to APP.
It is now well understood that APP is first cleaved at major ␣-and minor ␤-sites in its extracellular juxtamembrane region and that this releases the large extracellular amino-terminal domain (sAPP␣/␤) and generates the intracellular carboxylterminal fragments (CTF␣/␤) (17) . We first examined whether the Alcs also undergo cleavage at a primary site that generates a large extracellular amino-terminal domain (sAlc) and a short cytoplasmic carboxyl-terminal fragment (CTF1). Thus, FLAGAlc␣1, FLAG-Alc␤, and HA-Alc␥ were overexpressed in HEK293 cells (Fig. 1, B-D , middle lanes), as was APP (Fig. 1A , middle lane). The cell lysates were analyzed by Western blotting with the indicated antibodies (Cell). The sAlcs and sAPP were also recovered from the medium by immunoprecipitation with tag-specific antibodies and analyzed by Western blotting with the same antibody (Medium). The ϳ30-kDa CTF1 for Alc␣ and Alc␥ and the ϳ21-kDa CTF1 for Alc␤ were detected in the cell lysates along with the intact Alc proteins. At the same time, the sAlc fragments were detected in the medium. Thus, the Alcs are cleaved by a primary cleavage event, similar to APP.
The APP CTFs are secondarily cleaved at ␥-and/or ⑀-sites by the ␥-secretase complex, which results in the secretion of p3 or A␤ and releases the AICD (18) . It is now well documented that the APP CTFs accumulate in the cell in the presence of the ␥-secretase inhibitor L-685,458 (Fig. 1A) (19) . This suggests that use of L-685,458 may help to determine whether other type I membrane proteins can be cleaved by ␥-secretase. Thus, we assessed whether the Alcs proteins are ␥-secretase substrates by using L-685,458. In the cells expressing Alc␣1 or Alc␥, the intracellular levels of CTF1 increased dramatically in the presence of L-685,458 (Fig. 1, B and D, compare right and middle lanes). This suggests that Alc␣ and Alc␥ are potential substrates of ␥-secretase, as is APP (in Fig. 1A , compare right and middle lanes). In contrast, the intracellular levels of the CTF1 of Alc␤ did not change in the presence of L-685,458 (Fig.  1C , compare right and middle lanes). This may indicate that Alc␤ is not a substrate of the L-685,458-sensitive protease. However, we cannot rule out the possibility that the CTF1 of Alc␤ may be further cleaved by an L-685,458-insensitive protease (as suggested by the data in Fig. 3 ). The production of the (12) were transfected with or without pcDNA3-FLAG-hAlc␣1 (1.5 g). The cell lysates (ϳ20 g of protein) were analyzed by Western blotting with UT83. The numbers refer to the molecular masses (kDa) of the protein standards.
sAlcs was not largely altered by L-685,458 treatment ( Fig. 1 , B-D, bottom panels). This indicates that the inhibitor does not affect the primary cleavage event of Alcs. These observations support the notion that ␥-cleavage of Alcs follows their primary cleavage, which is very similar to how APP is metabolized.
We also showed that Alc is cleaved by a PS-dependent ␥-secretase. The ␥-secretase complex is composed of at least PS, Nicastrin, Aph-1, and Pen-2, and PS is an essential component for ␥-secretase activity (20 -22) . We examined the generation of the CTF1 molecules from endogenous Alc␣1 protein by PS1-deficient, PS1-and PS2-deficient, and wild type fibroblasts (16) (Fig. 1E) . The PS1-deficient cells showed an increase in intracellular CTF1 levels, because the ratio of CTF1 levels to holo Alc␣1 levels in these cells was 5-fold higher than the ratio in wild type fibroblasts. Moreover, the fibroblasts that lacking both PS1 and PS2 showed a remarkable accumulation of intracellular CTF1 (14-fold). An identical observation was also obtained when the ␥-secretase inhibitor L-685,458 was applied to wild type fibroblasts (data not shown). In a separate study, we expressed either wild type PS1 or the dominant negative mutant PS1D385A (wherein Asp 385 is substituted with Ala) (12) in HEK293 cells along with FLAG-Alc␣1 and then examined the generation of CTF1 (Fig. 1F) . The cells expressing the mutant PS1 accumulated CTF1. These results show clearly that Alc␣ is cleaved by PS-dependent ␥-secretase. Identical analyses with Alc␤ and Alc␥ are currently underway.
Secretion of A␤-like Peptide and Release of the Intracellular Domain
Fragment by the ␥-Cleavage of Alc CTF1-The above observations indicate that Alc is subjected to a primary cleavage event that generates CTF1 and that CTF1 is then cut by a secondary PS-dependent ␥-cleavage. It is likely that the later event results in the secretion of a short peptide (␤-Alc) and the release of AlcICD into the cytoplasm. We first determined the primary cleavage site of Alc␣ by subjecting the CTF1 of Alc␣1 to automated sequence analysis. The amino-terminal amino acid sequence was XXXPXFVX. Based on the protein sequence that was deduced from the Alc␣1 cDNA sequence, it appears that the amino-terminal sequence of the Alc␣1 CTF1 is 816 AAQPQFVH 823 . Thus, the most likely primary cleavage site of Alc␣1 is the peptide bond between Met 815 and Ala 816 (for the Alc␣2 isoform, which is identical to Alc␣1 apart from an additional 10 amino acids between the Alc␣1 residues at position 71 and 72 (9), the cleavage site that would generate the Alc␣2 CTF1 would be between Met 825 and Ala 826 ). We designated this cleavage site, which is in the extracellular domain, (Fig. 2A) . We also determined the amino-terminal amino acid sequence of holo Alc␣1. The determined sequence was ARVNK, which is identical to the Ala (9) . TM, transmembrane domain. B, expression of FLAG-tagged Alc␣1 and Alc␣⌬E proteins in HEK293 cells. HEK293 cells (ϳ1 ϫ 10 6 cells) were transiently transfected with pcDNA3-FLAG-hAlc␣1 (FLAG-Alc␣1), pcDNA3-FLAG-hAlc␣⌬E (Alc␣⌬E), or pcDNA3 (Vector) (1.5 g plasmid). The cell lysates (ϳ20 g of protein) were analyzed by Western blotting with the anti-FLAG antibody M2 (left panel) or the anti-Alc␣ antibody UT83 (right panel). C, secretion of ␤-Alc␣ from Alc␣⌬E. HEK293 cells (ϳ1 ϫ 10 7 cells) were transfected with (ϩ) or without (Ϫ) pcDNA3-FLAG-hAlc␣⌬E (6 g) and cultured for 24 h in the presence or absence (Ϫ) of the ␥-secretase inhibitors, compound E (Cpd.E; 50 nM), DAPT (1 M), or L-685,458 (1 M). The medium (6 ml) and cell lysate (Cell, 200 g of protein) were subjected to immunoprecipitation and then analyzed by Western blotting with the M2 antibody. The arrows labeled ␤-Alc␣ indicate the peptides that were generated by the ␥-secretase cleavage of Alc␣⌬E. D, ␤-Alc␣ is not generated in PS-deficient cells. Wild type (PS1 ϩ/ϩ, PS2 ϩ/ϩ), PS1-deficient (PS1 Ϫ/Ϫ, PS2 ϩ/ϩ), and PS1-and PS2-deficient (PS1 Ϫ/Ϫ, PS2 Ϫ/Ϫ) fibroblasts (2 ϫ 10 7 cells) were transfected with pcDNA3-FLAG-Alc␣⌬E (ϩ, 6 g). The medium (6 ml) and cell lysates (Cell, 200 g of protein) were subjected to immunoprecipitation and analyzed by Western blotting with the M2 antibody (left panel). The levels of ␤-Alc␣ (a relative ratio) were normalized by the amount of intracellular Alc␣⌬E, and these values were then converted so that they were relative to the level in wild type fibroblasts, which was assigned a reference value of 1.0 (right panel). The results shown are the average of duplicate assays, and the error bars are indicated.
cates that the signal peptidase cleaves the peptide bond between Ala 28 and Ala 29 of Alc␣, which means that the aminoterminal 28 residues constitute the signal peptide.
To demonstrate that Alc secretes an A␤-like peptide by the secondary cleavage of CTF1 by ␥-secretase, we designed the Alc␣⌬E construct, which lacks the sequence between Pro 40 and Met 815 in FLAG-Alc␣1 and mimics CTF1 ( Fig. 2A) . The FLAGtagged Alc␣1 or Alc␣⌬E protein was then expressed in HEK293 cells, and the cell lysates were probed with the anti-FLAG antibody M2 or the UT83 antibody that recognizes the carboxyl-terminal region of Alc␣ (Fig. 2B ). M2 (left panel) and UT83 (right panel) recognized both the FLAG-Alc␣1 and Alc␣⌬E proteins. UT83 also recognized the CTF1 that was generated from FLAG-Alc␣1 by -cleavage (right panel, middle lane). Alc␣⌬E migrated to almost the same position as CTF1 (ϳ30 kDa) on SDS-PAGE (Fig. 2B , right panel, compare the middle and right lanes).
We then examined whether the A␤-like peptide (we termed it ␤-Alc␣) is generated from Alc␣⌬E by ␥-cleavage. HEK293 cells expressing Alc␣⌬E were cultured with or without various ␥-secretase inhibitors, namely compound E (23) 24), or L-685,458. The medium and cell lysates were subjected to immunoprecipitation with the anti-FLAG antibody, after which the immunoprecipitates were separated on a Tris-Tricine gel (17.5% (w/v) polyacrylamide) and detected by Western blotting with the same antibody (Fig. 2C) . In the absence of inhibitors, ␤-Alc␣ was detected in the medium as a pair of ϳ5-kDa fragments (upper panel), but it was not recovered from the cell lysate (data not shown). However, in the presence of the inhibitors, the ␤-Alc␣ was not detected, which indicates that ␤-Alc␣ is generated from Alc␣⌬E by ␥-cleavage. Because two bands were observed, Alc␣ may be cleaved at two different sites by ␥-secretase. That the production of ␤-Alc␣ is dependent on ␥-secretase was confirmed by using PS-deficient cells (Fig. 2D) . Alc␣⌬E was expressed in PS1-deficient, PS1-and PS2-deficient, or wild type fibroblasts and the secretion of ␤-Alc␣ into the medium was examined. The secretion was decreased in PS1-deficient cells because the ratio of the secreted ␤-Alc␣ levels to the intracellular Alc␣⌬E levels was 30% of the ratio in wild type fibroblasts. Moreover, ␤-Alc␣ secretion was almost completely suppressed in the PS1-and PS2-deficient cells. These observations demonstrate that ␤-Alc␣ is generated by PS-dependent ␥-secretase cleavage and then secreted into the extracellular milieu.
When the membrane fraction of cells expressing APP is incubated in vitro, the intracellular domain fragment of APP (AICD) is generated by ␥/⑀-cleavage. AICD can be visualized in this case because it is not subjected to rapid intracellular degradation (25, 26) . We performed the same procedure to detect AlcICD. Thus, the membrane fractions of HEK293 cells expressing Alc␣1, Alc␤, or Alc␥ were incubated for 1 or 3 h at 37°C in the presence or absence of L-685,458. The Alc␣-, Alc␤-, and Alc␥-ICD molecules were then detected by Western blot analysis with the Alc-specific cytoplasmic domain antibodies (Fig. 3A) . The ϳ25-kDa Alc␣ICD, ϳ18-kDa Alc␤ICD, and ϳ25-kDa Alc␥ICD fragments were generated from the membranes. The molecular masses on SDS-PAGE did not agree with the AlcICD sizes that were deduced from their amino acid sequences (please see supplementary Fig. 2 ), probably because these molecules all contained a large acidic region (9) . L-685,458 inhibited the generation of these AlcICD molecule, which suggests that they were generated by the ␥-secretase cleavage of the Alcs. Notably, Fig. 1C contradicts this result because it indicates that the CTF1 of Alc␤ does not accumulate in Alc␤-expressing cells when they are treated with L-685,458. One possibility is that there may be two types of ␥-secretase enzymes in the cell, only one of which is sensitive to L-685,458. Alc␤ may be the substrate for the L-685,458-insensitive enzyme in vivo, but the membrane isolation and/or incubation may disturb the localization of the two enzymes. As a result, Alc␤ may be preferentially cleaved by the L-685,458-sensitive enzyme in vitro.
It is important to demonstrate that the generation of CTF1 and AlcICD is physiological metabolism of Alc in the brain. Thus, mouse brain lysate was homogenized, and the endogenous Alc␣ protein and its metabolic products were detected by Western blotting with the anti-Alc␣ cytoplasmic antibody UT83 (Fig. 3B) . We detected the endogenous CTF1 and Alc␣ICD fragments along with the holo Alc␣ protein. The asterisks in Fig. 3B may be an N-glycosylated form of CTF1 because these bands disappeared after treatment with N-glycosidase F (data not shown). These data demonstrate that the primary and secondary cleavages of Alc␣ that generate CTF1 and AlcICD are physiological events that occur in vivo. 
Synergic Stabilization of Alc␣ and APP Metabolism Because of the Formation of a Tripartite
Complex with X11L-We found previously that Alc enhances the X11L-dependent stabilization of APP metabolism (9). Because the above experiments demonstrated that the Alc proteins are metabolized in a similar manner as APP, we examined whether APP can enhance the X11L-dependent stabilization of Alc metabolism by forming a tripartite complex comprised of Alc, X11L, and APP. If it can, we would suggest that the mechanisms of Alc and APP are regulated coordinately by the formation and dissociation of the tripartite complex.
To examine this possibility, FLAG-Alc␣1 was expressed with or without X11L in the presence or absence of APP, and the secretion of sAlc␣1 was quantified along with the holo Alc␣1 levels in the cell lysates (Fig. 4) . The expression of X11L without APP suppressed sAlc␣1 secretion to ϳ60% of the levels secreted by cells that were only transfected with FLAG-Alc␣1 (compare lanes 2 and 3) . However, co-expression of X11L and APP strongly suppressed sAlc␣1 secretion to ϳ15% (compare lanes 2 and 5). Expression of APP on its own did not affect sAlc␣1 secretion (compare lanes 2 and 4) . In cells expressing X11L, the levels of intracellular Alc␣1 increased (lanes 3 and 5), which suggests that X11L stabilizes the intracellular metabolism of Alc␣1. That X11L and APP were indeed expressed was confirmed (Fig. 4 , left panels, lower two panels). As described previously (9), the intracellular metabolism of APP is stabilized by the co-expression of X11L and Alc␣1 (compare lanes 4 and 5). The endogenous X11L and APP695 levels in the cells were below the detection level (lane 1). These observations together show that the primary event that metabolizes Alc␣1 and produces sAlc␣1 is regulated by X11L in an identical manner as sAPP secretion (9) . Thus, the primary metabolic events of APP and Alc␣ may be coordinated.
In cells that co-expressed X11L, FLAG-Alc␣1, and APP, higher levels of X11L were recovered along with Alc␣1 by the FLAG-specific antibody than when APP was not present (please see supplementary Fig. 1 ). It was also observed that higher levels of X11L were recovered along with APP by the anti-APP antibody when Alc was co-expressed (Ref. 9 and supplementary Fig. 1 ). These observations suggest that the coordinated metabolism of APP and Alc, at least with regard to the secretion of extracellular domain caused by cleavage at the -site, is regulated by the formation of a tripartite complex that is mediated by the intracellular association of Alc and APP with X11L.
We also previously demonstrated that Alc enhances the X11L-dependent inhibition of the ␥-cleavage of APP CTF␤ (9) . Thus, we next examined whether APP can enhance the X11L-dependent inhibition of the ␥-cleavage of Alc CTF1. Alc␣⌬E and PS1 were expressed in HEK293 cells with or without X11L in the presence or absence of APP (Fig. 5A ). The production of ␤-Alc␣ was decreased by X11L co-expression, and APP enhanced this effect (compare lanes 3 and 5 with lane 2). The secreted ␤-Alc␣ levels were quantified and indicated as a relative ratio. Expression of APP alone does not have any effect on ␤-Alc␣ secretion (lane 4). It has been well documented that the APP CTFs can be shown to interact with PS1 by a co-immunoprecipitation assay when the cells are treated with N-acetyl-leucyl-norleucinal (LLnL) (27) . Because Alc is a PS substrate, it is likely that Alc␣⌬E also interacts with PS1. To test this, Alc␣⌬E and PS1 were expressed in HEK293 cells in the presence or absence of LLnL (Fig. 5B) . Alc␣⌬E was recovered by immunoprecipitation with an anti-FLAG antibody, and these immunoprecipitates (IP) were analyzed by Western blotting with anti-FLAG and anti-PS1 antibodies. In the presence of LLnL, the full-length PS1 protein and both the amino-and carboxyl-terminal fragments of PS1 were recovered along with Alc␣⌬E. Even in the absence of LLnL, a strong interaction between the aminoterminal fragment of PS1 and Alc⌬E was observed. This indicates that the Alc CTF1 can interact with PS1. Therefore, we examined whether the co-expression of X11L and APP can inhibit the interaction of Alc␣⌬E with PS1, similar to how the co-expression of X11L and Alc inhibits the interaction of APP CTF␤ with PS1 (9). HEK293 cells expressing Alc␣⌬E and PS1 in the presence or absence of X11L with or without APP were assayed (Fig. 5C) . We observed that, in the presence of X11L, the M2 antibody recovered a smaller amount of PS1 (compare lanes 2 and 3), which indicates that X11L suppressed the interaction between Alc␣⌬E and PS1. Surprisingly, when APP was co-expressed along with X11L, it completely abolished the interaction between Alc␣⌬E and PS1 (lane 5). This suggests that APP enhanced the inhibitory effect of X11L by forming a stable complex comprised of Alc␣⌬E, X11L, and APP. These observations indicate that X11L blocks the association of Alc␣⌬E with PS1, thereby suppressing the generation of ␤-Alc␣. This is identical to how X11L suppresses the generation of A␤ derived from CTF␤. These data together suggest that APP and Alc are likely to be synergistically stabilized by forming a complex via X11L and that their metabolism in the cell is probably coordinated by the dissociation of X11L from this complex. FIG. 4 . Effect of co-expressing X11L and APP on sAlc␣1 secretion. HEK293 cells (ϳ1 ϫ 10 6 cells) were transiently transfected with pcDNA3-FLAG-hAlc␣1 (0.5 g) (see Fig. 2A for the construct) with or without pcDNA3-hX11L (0.5 g) and in the presence or absence of pcDNA3APP695 (0.5 g). To standardize the plasmid amounts, pcDNA3 vector (Ϫ) was added. The culture medium (1 ml) was collected, and sAlc␣1 was recovered by immunoprecipitation with the anti-FLAG antibody M2. The immunoprecipitates (Medium) and cell lysates (Cell, ϳ20 g of protein) were analyzed by Western blotting with the M2 (sAlc␣1 and Alc␣1), mint2 (X11L), and G369 (APP) antibodies (left panel). The levels of sAlc␣1 (a relative ratio) were normalized by the amounts of intracellular holo Alc␣1, and these values were then converted so that they were relative to the level in lane 2, which was assigned a reference value of 1.0 (right panel). The results shown are the averages of duplicate assays, and the error bars are indicated.
Stabilization and Localization of AlcICD by Interacting with FE65-It is well documented that AICD associates with FE65
and that this interaction stabilizes intracellular AICD metabolism (28) . Like AICD, AlcICD possess a X11L-binding motif to which FE65 is expected to bind. To assess this, HEK293 cells were transfected with pcDNA3.1NFLAG-FE65 and pcDNA3-Alc␣ICD or pcDNA3-Alc␣ICD/NPAA. In the latter construct, the NPMETY sequence of Alc␣ICD has been altered to AAMETY, which should prevent AlcICD from interacting with X11L (9). The overexpressed Alc␣ICD protein was identical in size to the Alc␣ICD that was generated endogenously from Alc␣ (please see supplementary Fig. 2) . A co-immunoprecipitation assay using the anti-FLAG antibody recovered Alc␣ICD, but not Alc␣ICD/NPAA, along with FLAG-FE65 (Fig. 6A, left  panel) . This result demonstrates that like AICD, AlcICD can associate with FE65. We also confirmed that FE65 associates with endogenously generated Alc␣ICD by immunoprecipitating lysates of HEK293 cells expressing FLAG-FE65 and Alc␣1 or APP with the anti-FLAG antibody. The IP were analyzed by Western blotting with the anti-Alc␣1 cytoplasmic UT83 or the anti-APP cytoplasmic G369 antibody (Fig. 6A, right panel) . As expected, FE65 associated with APP (middle lane). The anti-FLAG antibody also co-precipitated the full-length Alc␣1, Alc␣1 CTF1, and Alc␣ICD along with FLAG-FE65 (right lane). This indicates that FE65 can interact with endogenously generated Alc␣ICD within cells.
We next examined whether FE65 can stabilize AlcICD metabolism. FLAG-Alc␣1 was expressed in HEK293 cells with or without FE65 in the presence or absence of L-685,458, and the intracellular levels of FLAG-Alc␣1, Alc␣1 CTF1, and Alc␣ICD were analyzed by Western blotting with the anti-Alc␣ antibody UT83 (Fig. 6B, left panel) . The faint level of Alc␣ICD that was produced in cells expressing FLAG-Alc␣1 could be detected by longer exposure of the film (left lower panel). The amount was increased when FE65 was co-expressed, whereas L-685,458 inhibited the intracellular generation of Alc␣ICD. Because Alc␣ICD was recovered in the cytoplasmic S100 but not the membrane P100 fraction of FLAG-Alc␣1-expressing HEK293 cells (Fig. 6B, right panel) , it is likely that FE65 stabilizes the metabolism of Alc␣ICD after it has been released into the cytoplasm. Thus, AlcICD is metabolically stabilized by its association with FE65 in the cytoplasm, which is also true for AICD (28) .
It has been reported that AICD translocates into the nucleus followed by its association with FE65 (29) . Thus, we explored the intracellular localization of AlcICD in the presence or absence of FE65 (Fig. 6C) . Alc␣ICD overexpressed on its own showed a predominantly cytoplasmic localization (upper panels). However, when Alc␣ICD was co-expressed with FE65, Alc␣-ICD localized in the nucleus (lower panels), which suggests that Alc␣ICD is translocated into the nucleus because of its association with FE65. Thus, AlcICD is very similar to AICD with regard to its metabolism and localization.
AICD-and FE65-dependent Gene Transactivation Is Regulated by AlcICD-AICD is able to transactivate gene(s) after it interacts with FE65 (30) . Because AlcICD associates with FE65 and translocates into the nucleus, as does AICD, we assessed whether AlcICD can also transactivate genes. When the Gal4-AICD fusion protein is expressed in SHSY5Y cells with or without FLAG-FE65 and the reporter gene activity is quantified, as reported elsewhere (30) , reporter gene transactivation activity is observed in the presence of FE65 (Fig. 7A, compare  columns 3 and 4) . When we substituted Gal4-AICD in this experiment with Gal4-Alc␣ICD, however, FE65-dependent FIG. 5. X11L suppresses ␤-Alc␣ generation and inhibits the interaction between PS1 and Alc␣ CTF1, and this is enhanced by the formation of a tripartite complex between X11L, Alc␣ CTF1, and APP. A, effect of co-expressing X11L and APP on the generation of ␤-Alc␣. HEK293 cells (ϳ1 ϫ 10 7 cells) were transiently transfected with pcDNA3-FLAG-hAlc␣⌬E (1.5 g) and pcDNA3-PS1 (1.5 g) in the presence or absence of pcDNA3-hX11L (1.5 g) with or without pcDNA3APP695 (1.5 g). To standardize the plasmid amounts, pcDNA3 vector (Ϫ) was added to yield 6.0 g of plasmid in total. The cells were cultured for 24 h, and the culture medium (6 ml) was immunoprecipitated with the anti-FLAG antibody. The immunoprecipitates were then analyzed by Western blotting with M2. The levels of ␤-Alc␣ (a relative ratio) were normalized by the amount of intracellular Alc␣⌬E (data not shown), and these values were then converted so that they were relative to the levels shown in lane 2, which was assigned a reference value of 1.0. The results are the averages of duplicate assays, and the error bars are indicated. B, interaction of Alc⌬E with PS1. HEK293 cells (ϳ1 ϫ 10 6 cells) were transiently transfected with pcDNA3-FLAG-hAlc␣⌬E (0.75 g) and pcDNA3-PS1 (0.75 g). To standardize the plasmid amounts, pcDNA3 vector (Ϫ) was added to yield 1.5 g of plasmid in total. The cells were cultured for 24 h in the presence (ϩ) or absence (Ϫ) of LLnL (10 M) and then lysed. The cell lysates were immunoprecipitated with the anti-FLAG antibody M2, and the IP and cell lysates (20 g of protein) were analyzed by Western blotting with the anti-FLAG M2 (Alc␣⌬E), the anti-PS1 amino-terminal fragment (FL and NTF), and the anti-PS1CTF antibodies. FL, full length of PS1; NTF, amino-terminal fragment of PS1; CTF, carboxyl-terminal fragment of PSI. C, effect of X11L and APP on the interaction of Alc␣⌬E with PS1. HEK293 cells (ϳ1 ϫ 10 6 cells) were transiently transfected with pcDNA3-FLAG-hAlc␣⌬E (0.375 g) and pcDNA3-PS1(0.375 g) in the presence or absence of pcDNA3-hX11L (0.375 g) with or without pcDNA3APP695 (0.375 g). To standardize the plasmid amounts, pcDNA3 vector (Ϫ) was added to yield 1.5 g of plasmid in total. The cells were cultured for 24 h in the absence of LLnL and then lysed. The cell lysates were immunoprecipitated with the anti-FLAG antibody M2, and the immunoprecipitates were analyzed by Western blotting with antibodies specific for FLAG (Alc␣⌬E), the amino-terminal half of PS1 (PS1), X11L (mint2), and APP (G369).
gene transactivation activity was not observed (compare columns 7 and 8). This indicates that AlcICD itself does not possess gene transactivation activity. Surprisingly, however, when Alc␣ICD was co-expressed with Gal4-AICD and FE65, the gene transactivation mediated by AICD was almost completely suppressed (compare columns 4 and 5). When the same experiment was performed with Alc␣ICD/NPAA (which lacks FE65 binding ability) instead of Alc␣ICD, the AICD-mediated gene transactivation was not inhibited (compare columns 5 and 6).
One possibility that explains this suppressive ability of AlcICD is that it competes with AICD for FE65 binding. To test this, we performed a competitive immunoprecipitation assay (Fig. 7B) . Thus, FLAG-FE65 was co-expressed in HEK293 cells with GFP-AICD in the presence or absence of Alc␣ICD, and the cells were lysed and subjected to immunoprecipitation with the anti-FLAG antibody. The immunoprecipitates were then analyzed by Western blotting with the indicated antibodies (Fig.  7B, top set of panels) . In the absence of Alc␣ICD, the FLAG antibody co-immunoprecipitated a large amount of GFP-AICD along with FLAG-FE65, which indicates that these two molecules associate (lane 4). However, when Alc␣ICD was co-expressed along with FLAG-FE65 and GFP-AICD, the FLAG antibody recovered only a small amount of GFP-AICD along with a small amount of Alc␣ICD (lane 5). In contrast, when Alc␣ICD/NPAA was co-expressed, a large amount of GFP-AICD was again recovered (lane 6). When the immunoprecipitation was performed with the anti-APP antibody (middle set of panels), FE65 was co-precipitated (lane 4). Furthermore, in the presence of Alc␣ICD (lane 5) but not Alc␣ICD/NPAA (lane 6), FE65 was not recovered along with AICD. These observation suggest that the binding of FE65 to AICD is reduced in the presence of Alc␣ICD because Alc␣ICD competes with AICD for the association with FE65. This would explain why Alc␣ICD suppresses the gene transactivation by AICD. We also assessed whether Alc␣1 can regulate holo APP in the same way (please see supplementary Fig. 3 ). We found that the APP-Gal4 fusion protein showed reporter gene activation activity in the presence of FE65 but that this activity was suppressed by Alc␣1. Thus, endogenously generated AICD can activate FE65-dependent gene transactivation, and this function can be suppressed by the endogenously generated Alc␣ICD molecule. DISCUSSION We previously demonstrated that Alc forms a complex with APP in the brain through the cytoplasmic interaction with X11L, which acts to bridge Alc and APP (9) . Once this tripartite complex is formed, APP becomes very stable with regard to its metabolism, whereas in contrast the naked APP molecule is readily cleaved by the ␣-and/or ␤-secretases in the cell. Moreover, the CTF␤ also forms a tripartite complex with X11L and Alc. This blocks the access to CTF␤ by the ␥-secretase component PS1 and consequently decreases the generation of A␤ and AICD from CTF␤ by ␥-secretase. Without this suppressive regulation, the naked CTF␤ molecule generates large amount of A␤ because of cleavage by ␥-secretase (9). Alc is a type I transmembrane protein that bears the same receptor-like structure as APP. We and another group have found that the Alcs/calsyntenins are, like APP, cleaved extracellularly (this paper and Ref. 10). In the study reported here, we determined the primary cleavage site of Alc␣1 and located it in the extracellular juxtamembrane region. This suggests that CTF1, the cytoplasmic domain fragment of Alc␣1 generated by this primary cleavage, can subsequently be cleaved by ␥-secretase, as is APP. Supporting this, we demonstrated here that Alc is a novel substrate of ␥-secretase. Recent publications have reported that a number of membrane proteins can act as ␥-secretase substrates (31) (32) (33) (34) (35) (36) (37) (38) (39) (40) (41) . Thus, it is now clear that there are a variety of ␥-secretase substrates and that ␥-secretase is not specific for APP and Notch (42) .
A novel indication of our observation that Alc is cleaved by ␥-secretase is that the ␥-secretase-mediated cleavages of APP and Alc should be coordinated. We found that when Alc forms tripartite complex with X11L and APP, its primary cleavage is suppressed, and the generation of sAlc and CTF1 is strongly inhibited. In contrast, the naked Alc molecule is quickly cleaved at the primary -site. This metabolic pattern is identical to the pattern of APP metabolism. Furthermore, when Alc␣⌬E, which mimics the CTF1 product of the primary cleavage, was expressed in cells, we could detect A␤-like short peptides (␤-Alc␣) in the medium. These peptides are likely to be the amino-terminal products of the ␥-cleavage of Alc␣⌬E. However, when Alc␣⌬E formed a tripartite complex with X11L and APP, the cleavage of Alc␣⌬E by ␥-secretase was suppressed because the interaction between Alc␣⌬E and PS1 was suppressed. CTF␤ cleavage by PS1 is regulated by an identical mechanism (9). These observations together support the hypothesis that APP and Alc are coordinately metabolized because when both proteins form a complex through their intra- . Thus, the tripartite complex synergically stabilizes APP and Alc metabolism. When X11L dissociates from the complex, APP and Alc are simultaneously cleaved in a coordinated fashion at first their primary cleavage sites and then at their secondary sites. The naked APP protein thus generates A␤ (or p3) and AICD followed by the production of sAPP and CTF␤ (or CTF␣), whereas the naked Alc protein generates ␤-Alc and AlcICD followed by the production of sAlc and CTF1. AICD associates with FE65 and shows gene transactivation activity. AlcICD also associates with FE65 and can inhibit the FE65-dependent gene transactivation activity of AICD by blocking the association between AICD and FE65 in the cytoplasm and/or the nucleus. Thus, FE65-dependent gene transactivation was reciprocally regulated by association of AICD or AlcICD with FE65. cellular interaction with X11L, their primary and secondary cleavages are remarkably suppressed. However, when the tripartite complex is dissociated into free components, APP and Alc are readily subjected to be cleaved (Fig. 8) . This coordinated regulation suggests that if the complex formation in the neuron is disturbed in some way, as it may occur in the AD brain, both proteins will be subjected to unregulated cleavage that leads the increased production of A␤ and ␤-Alc. It will be of interest to assess whether there is a difference in the formation of complexes composed of APP or APP CTFs, X11L or X11, and Alcs or Alc CTF1 in AD and healthy brains.
The ␥-cleavage of APP CTFs generates the cytoplasmic fragment AICD, which plays an important role in gene transactivation after it associates with FE65 (30) . Other membrane proteins such as Notch and CD44 are similar to APP in this gene transactivation function (36, 43) . Because AlcICD can also bind to FE65, we consequently expected AlcICD to be able to transactivate genes. However, surprisingly, AlcICD did not show gene transactivation activity even in the presence of FE65. Indeed, we found that AlcICD actually suppressed the FE65-dependent gene transactivation activity of AICD. One possible explanation for this interesting observation is that AlcICD competes with AICD for FE65 prior to the nuclear localization of the AICD and FE65 complex (Fig. 8) . This possibility is supported by our findings that in the absence of AlcICD, FE65 immunoprecipitates contain large amounts of AICD, but less AICD is co-precipitated in the presence of AlcICD. Moreover, an antibody specific for AICD failed to coimmunoprecipitate FE65 in the presence of AlcICD. However, because we found that Alc␣ICD can translocate into the nucleus in the presence of FE65, it cannot be ruled out that the complex of AlcICD and FE65 may inhibit AICD-and FE65-dependent gene transactivation in the nucleus. In any case, it is clear that the generation of AlcICD suppresses AICD-dependent gene transactivation activity. Thus, we can postulate that the AlcICD serves as a molecular switch that regulates AICDdependent gene transactivation.
Unlike the Notch-Delta/Serrate system, APP and Alc are likely to be constitutively subjected to primary extracellular cleavage without stimulation by extracellular ligand(s). However, the products of the primary cleavage events, namely, APP CTF␣/␤ and AlcCTF1, will not be continually cleaved by ␥-secretase if they form a tripartite complex through their interactions in the cytoplasm with X11L. Thus, in healthy neurons, the generation of AICD and AlcICD is likely to be regulated by their mutual association with X11L. As a result of this cooperative metabolism, the gene transactivation function of AICD may be controlled by AlcICD. In conclusion, as deduced from the present work and our previous studies (5, 8, 9) , the generation of AICD and the gene transactivation function of AICD appear to be regulated by interactions of APP and/or AICD with a variety of proteins, including X11L, FE65, Alc, and AlcICD. A schematic depiction showing the coordinated metabolic regulation of APP and Alc and the down-regulation of APP-dependent gene transactivation by Alc is shown in Fig.  8 . A disorder in the metabolism of APP and Alc that abolishes the coordination of their cleavages could unbalance the generation of AICD and AlcICD and may lead the unregulated expression of gene(s) transactivated by AICD. This may accelerate the neurodegeneration that is already underway because of the neuronal toxicity of the increased levels of A␤. Alternatively, aberrant gene transactivation raised by an increased production of AICD may be suppressed by the coordinated and increased production of AlcICD to preserve normal neuronal function(s). Future analysis that examine how AICD-dependent gene transactivation is regulated by the coordinated generation of AlcICD may reveal one of novel molecular mechanism underlying the neuronal cell dysfunction and death that characterizes AD.
